Evidence is available from retrospective analysis of the CPARIE trial with
clopidogrel that patients who have atherosclerosis in other vascular beds, such as prior ischemic stroke or concurrent peripheral vascular disease, benefit from receiving clopidogrel over aspirin. Some cardiologists have concluded that these patients, who are at higher risk of a subsequent vascular event, would benefit from combined therapy.